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Cytomegalovirus (CMV) is a ubiquitous member of the family 
Herpesviridae. It persists in the body like other herpesviruses, 
resulting in latency. It is continually suppressed by cell-mediated 
immunity, so infection is usually asymptomatic in immunocompetent 
hosts. CMV retinitis is a relentless vision-threatening infection that 
can cause irreversible vision loss within weeks to months.[1] Most 
cases are diagnosed clinically, as it has a characteristic fundoscopic 
appearance. The classic appearance is a ‘bushfire-like’ extension along 
the course of the retinal vascular arcades that may involve the optic 
nerve head (Fig. 1).
CMV retinitis is the most common cause of vision loss in patients 
with AIDS.[2] It is an opportunistic infection and a late manifestation 
of HIV infection, usually associated with CD4 counts of <50 cells/
µL.[3] Before the advent of highly active antiretiroviral therapy 
(HAART), treatment of CMV retinitis was lifelong and mortality 
rates due to HIV were high. With the advent of HAART, there has 
been a 75% reduction in the number of new cases of CMV retinitis.[4]
The principles of treatment of CMV retinitis are to improve the 
patient’s immune function and to use specific anti-CMV agents to 
inhibit viral replication. Many studies have investigated the effect 
of HAART on CMV retinitis.[5] The incidence and recurrence rates 
have been shown to decrease as a result of the restored immunity that 
HAART provides.[6] In addition, anti-CMV treatment can usually be 
discontinued once immune reconstitution has occurred.
CMV targeted treatment options include intravenous, oral 
and intravitreal antivirals. Intravitreal ganciclovir has been the 
mainstay of treatment for CMV retinits in South Africa (SA) and 
has been shown to have a better pharmacokinetic profile than 
intravitreal foscarnet,[7] although recent evidence[8] suggests that 
systemic treatment should be considered. Systemic treatment has a 
higher risk of side-effects than ocular treatment and has significant 
cost and resource implications. Ganciclovir causes haematological 
abnormalities (anaemia, neutropenia and thrombocytopenia) and 
may result in long-term reproductive complications.[9] Foscarnet is 
highly nephrotoxic and must be administered with caution to patients 
with renal disease. Oral valganciclovir has a bioavailability of 60% 
and can be used as an adjunct for both induction and maintenance 
therapy. At the time of this study, intravitreal ganciclovir alone, 
without systemic anti-CMV treatment, was used to treat all patients 
with CMV retinitis. The decision when to stop anti-CMV therapy 
depends upon many factors, including rising CD4 counts, decreasing 
systemic HIV viral load, duration of HAART and inactivity of CMV 
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Fig. 1. Cytomegalovirus infection with typical ‘bushfire-like’ extension along 
the vascular arcades with retinal necrosis.
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lesions.[4] The US Public Health Service provided guidelines in 
1999[10] suggesting the discontinuation of anti-CMV therapy after 
patients with quiescent retinitis achieve sustained immune recovery, 
defined as CD4 counts of ≥100 cells/µL for at least two consecutive 
visits at least 6 months apart.
Objectives
To review the clinical features, management and outcome of CMV 
retinitis at Groote Schuur Hospital, Cape Town, SA, over a 10-year 
period, and to compare treatment protocols of 13 public hospitals in 
SA that treat patients with CMV retinitis.
Methods
A retrospective record review of patients diagnosed with CMV 
retinitis between 1 January 2003 and 1 January 2013 was performed. 
Only patients with polymerase chain reaction (PCR)-proven CMV 
retinitis were included, and all patients were followed up for at least 
1 month. Patients with CMV retinitis who had co-infection with 
another organism (e.g. syphilis, herpes simplex) were excluded, 
as were patients in whom a poor fundal view precluded accurate 
assessment (Table 1).
The following parameters were recorded: age, sex, HIV status 
and CD4 count (if HIV-positive), presenting and follow-up visual 
acuity (VA) (best corrected VA), clinical features (macular and 
optic disc involvement, vitritis, vasculitis and number of retinal 
quadrants involved), PCR results, dates and number of intravitreal 
injections of ganciclovir, complications, whether prophylactic argon 
demarcation laser treatment was performed, and whether the second 
eye became involved. Best corrected VAs were converted from 
Snellen to LogMAR for statistical analysis.[11] We subdivided patients 
into three arbitrary categories according to VA, as follows: category 
1 – VA ≥6/18; category 2 – VA 6/24 - 6/60; and category 3 – VA <6/60.
A questionnaire was sent to 13 public hospitals in SA that treat 
patients with CMV retinitis, with questions on their diagnosis and 
treatment of the condition.
Ethics approval
Ethics approval was obtained from the University of Cape Town 
Human Research Ethics Committee (ref. no. 384/2014).
Results
One hundred and forty-one eyes of 91 patients were included in the 
study. Twenty-seven patients were excluded (Table 1). The median age 
was 33.6 years (range 14 - 58), and 60.4% (55/91) were female. Fifty 
patients had bilateral disease. Patients were followed up for a mean of 
8.1 months (range 1 - 56). Of these patients, 98.9% (90/91) were HIV-
positive, 72.5% (66/91) were on HAART at the time of presentation, 
and 41.7% (38/91) defaulted from or died during treatment.
Presenting VA of the involved eyes ranged from 6/6 (LogMAR 0.0) 
to no light perception. Fifty-five percent of eyes had a presenting 
Snellen VA of 6/60 (LogMAR 1.00) or worse. The presenting and final 
VAs are summarised in Fig. 2.
The number of intravitreal injections of ganciclovir ranged from 
0 to 29 per eye (mean 4.9). There was no association between the 
number of injections administered and the final visual outcome 
(Fisher’s exact test, p=0.17).
Presenting CD4 counts ranged from 1 to 478 cells/µL (mean 
58). There was no statistically significant difference in median final 
VA when comparing patients who presented with a CD4 count of 
<50 cells/µL with those with a count of ≥50 cells/µL (χ2 test, p=0.89).
Seventy-three percent of the patients were on HAART at presen-
tation. These patients had better final VA than those who were not 
on HAART (p<0.001). However, there was no statistically significant 
difference when comparing the number of injections needed to 
achieve disease resolution in patients on HAART with that in patients 
who were not on HAART (t-test, p=0.97).
Fifty percent of eyes had macular (central 20 degrees of vision) 
involvement on presentation, and in 48.2% (68/141) the margin 
of the optic disc was involved. Eyes with macular involvement on 
presentation had poorer visual outcomes than those in which the 
macula was spared (t-test, p<0.05). There was also a significant 
association between the number of retinal quadrants involved and 
final visual outcome (χ2 test, p<0.001) (Table 2).
Twenty-two percent of eyes developed retinal detachments. There 
was no statistically significant association between the number of 
retinal quadrants involved and the development of retinal detachment 
(χ2 test, p=0.40). Presenting CD4 count was also not associated with 
the development of retinal detachment (χ2 test, p=0.49).
Presenting VA was a strong predictor of final VA (χ2 test, p<0.01) 
(Table 3). Linear regression analysis showed that patients who 
presented with a VA of ≥6/18 had a 4.6 times higher chance than 
those who presented with a VA of <6/18 of obtaining a final VA of 
≥6/18 (p<0.01).
Responses to the questionnaire
Questionnaires were sent to 13 public health centres in SA that treat 
CMV retinitis (Table 4). Responses were received from nine centres 
Table 1. Patients excluded from the study
Reason for exclusion n
No PCR result 6
Refused treatment 3
Defaulted from treatment 4
Co-infection 6
Inadequate charting 3
Poor fundal view 2
Missing charts 3
Total included 91
PCR = polymerase chain reaction.
Fig. 2. Distribution of presenting and final VA (logarithmic scale). (VA = 
visual acuity; NLP = no light perception; LP = light perception; HM = hand 
movements; CF = counting fingers.)
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(69.2%). There was considerable variation in intravitreal ganciclovir 
injection intervals between centres, ranging from twice weekly to as 
needed. Follow-up and re-injection criteria also varied.
Six centres had fixed criteria for stopping anti-CMV treatment. 
They all varied slightly, and none of them strictly adhered to the 
1999 US Public Health Service guidelines[10] for the discontinuation 
of anti-CMV therapy. Three centres did not have fixed criteria, with 
decisions being made on a patient-by-patient basis. The majority 
of centres did not perform prophylactic argon demarcation laser 
treatment. All the centres that responded used intravitreal ganciclo-
vir as the primary treatment for CMV retinitis and referred HIV-
positive patients for antiretroviral work-up and treatment.
Discussion
This retrospective cohort study describes the spectrum of presenting 
features, clinical course and prognostic factors in patients presenting 
with CMV retinitis at Groote Schuur Hospital.
Independent risk factors associated with obtaining a better final 
visual outcome included good presenting VA, fewer retinal quadrants 
involved, absence of macular involvement and being on HAART 
at presentation. As would be expected, macular involvement had a 
significant effect on visual outcome compared with cases in which 
the macula was uninvolved (t-test, p<0.05). Presenting CD4 count 
and the number of injections received had no statistically significant 
correlation with final visual outcome in our study. In a similar study, 
patients who were on HAART at baseline had a lower relative risk of 
losing vision.[12]
We found that patients who were on HAART at the time of 
presentation had a better mean final VA that those who were not 
on HAART (t-test, p<0.01). Several other studies have shown that 
the introduction of HAART has led to a substantial decrease in 
the incidence and course of CMV retinitis.[3.6] Similarly, it has been 
shown that HAART considerably reduced the rate of CMV retinitis 
adverse events, from 0.35 to 0.14 per 100 patient-days at risk.[13]
All the patients treated during the study period received ocular anti-
CMV therapy only, as well as systemic antiretroviral treatment where 
indicated. A recent study[7] compared patients with CMV retinitis 
receiving ocular anti-CMV therapy alone with those receiving both 
ocular and systemic anti-CMV therapy and found a 50% reduction 
in mortality, a 90% reduction in new visceral CMV and an 80% 
reduction in involvement of the second eye in the systemic therapy 
group, although the number of patients in the group that received 
local treatment only was small (n=33).
A significant proportion (41.6%) of our study patients were lost to 
follow-up, which raises concern about possible missed cases of sys-
temic CMV-related morbidity and mortality. Over the mean follow-
Table 4. Summary of answers to the questionnaire
Centre Diagnosis
Treatment 
drug
Treatment 
regimen Follow-up
Re-injection 
criteria
Demarcation 
laser
CD4 
monitoring
ARV 
referral
1 Clinical + PCR Intravitreal 
ganciclovir
Weekly Re-evaluate Fundus photo Yes Yes Yes
2 Clinical Intravitreal 
ganciclovir
Twice weekly Set regimen Fundus drawing No Yes Yes
3 Clinical + PCR Intravitreal 
ganciclovir
Weekly Re-evaluate Fundus photo No Yes Yes
4 Clinical Intravitreal 
ganciclovir
Twice weekly Set regimen Fundus photo No Yes Yes
5 Clinical Intravitreal 
ganciclovir
Twice weekly Re-evaluate Fundus drawing Yes Yes Yes
6 Clinical Intravitreal 
ganciclovir
As needed Re-evaluate Fundus photo No No Yes
7 Clinical (PCR suspect) Intravitreal 
ganciclovir
Weekly Set regimen Fundus drawing No Yes Yes
8 Clinical Intravitreal 
ganciclovir
Twice weekly Set regimen Fundus drawing No Yes Yes
9 Clinical (PCR suspect) Intravitreal 
ganciclovir
Weekly Re-evaluate Fundus drawing No No Yes
PCR = polymerase chain reaction; ARV = antiretroviral; PCR suspect = PCR performed in cases where the clinical diagnosis is not certain.
Table 2. Retinal quadrants v. final VA (n (%) of eyes)
Final VA category
Number of 
quadrants involved 1 2 3 Total
1 17 (58.6) 3 (10.3) 9 (31.0) 29 (100)
2 11 (26.8) 14 (34.2) 16 (39.0) 41 (100)
3 4 (33.3) 3 (25.0) 5 (41.7) 12 (100)
4 11 (19.6) 13 (23.2) 32 (57.1) 56 (100)
Total 43 (31.2) 33 (23.9) 62 (44.9) 138* (100) 
VA = visual acuity; category 1 = VA ≥6/18; category 2 = VA 6/24 - 6/60; category 3 =  
VA <6/60.
*Three eyes did not have sufficient charting of this parameter.
Table 3. Presenting VA v. final VA (n (%) of eyes)
Final VA category
Presenting 
VA category 1 2 3 Total
1 26 (18.4) 5 (3.5) 6 (4.3) 37 (26.2)
2 10 (7.1) 10 (7.1) 7 (5.0) 27 (19.1)
3 7 (4.9) 18 (12.8) 52 (36.9) 77 (54.6)
Total 43 (30.3) 33 (23.5) 65 (46.2) 141 (100)
VA = visual acuity; category 1 = VA ≥6/18; category 2 = VA 6/24 - 6/60; category 3 =  
VA <6/60. 
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up of 8.1 months, 10 patients (11.0%) presented with or developed 
new visceral CMV. Involvement of the second eye occurred in one of 
the patients presenting with unilateral disease.
Resource limitations and cost have influenced treatment protocols 
in developing countries. A study in Singapore showed weekly 
ganciclovir injections as monotherapy to be an efficacious option 
for developing countries where newer options of sustained-release 
implants or oral valganciclovir are unavailable or prohibitively 
expensive.[13] In the light of the above findings and where resources 
allow, the addition of systemic anti-CMV therapy should be advocated 
to decrease morbidity and mortality.
Twenty-two percent of patients in our study developed retinal 
detachments. A large study of 494 eyes of 379 patients with CMV 
retinitis found a retinitis-related retinal detachment rate of 16.7%. [14] A 
further study looked at risk factors for developing retinal detachments 
in patients with CMV retinitis and found bilateral disease and lesion 
size to be the strongest predictors.[15] Our study failed to demonstrate 
an association between the number of retinal quadrants involved 
and retinal detachment, but we did not specifically measure lesion 
size. Prophylactic argon retinal photocoagulation has been successful 
in anecdotal reports and small case series,[16] but there is no 
uniformity among the centres in SA with regard to treating patients 
prophylactically with laser.
The decision when to stop anti-CMV therapy has been guided by 
the international literature, which has identified several important 
factors including rising CD4 counts, decreasing systemic HIV viral 
load, duration of HAART and inactivity of CMV lesions. There is 
a discrepancy among centres in SA regarding the decision when to 
stop therapy.
Forty-two percent of our patients defaulted from treatment or 
died during treatment. Patients with CMV retinitis usually have 
severe immunosuppression and are susceptible to a wide variety of 
other opportunistic infections. In our patient population, transport 
difficulties and social stigma are further barriers that may prevent 
optimal follow-up. Only 58.4% of patients were followed up until 
discharge from ophthalmology, and injection dates were often 
missed. Our study is limited further by its retrospective nature. 
Different clinicians examined patients at each visit, but this was 
overcome by using photos rather than drawings for comparison.
There is currently no national protocol for initiation, continuation 
and discontinuation of treatment for CMV retinitis. The only 
similarities between centres are the use of intravitreal ganciclovir 
as the mainstay of treatment and vague similarities regarding 
when to discontinue treatment. The most striking differences are 
in diagnostic methods (clinical v. PCR), intravitreal injection time 
interval, monitoring of CD4 counts and criteria for repeat injections.
Conclusions
CMV retinitis in HIV-positive patients is a vision-threatening 
opportunistic infection that requires aggressive and consistent 
treatment to preserve visual function. Intravitreal ganciclovir alone 
is a cost-effective and readily available method of controlling CMV 
retinitis.
Patients with CMV retinitis are most likely to have favourable 
visual outcomes when they present with better VA, have fewer 
retinal quadrants involved, do not have macular involvement and 
are on HAART. The converse is true for poor visual outcomes. The 
diagnosis and management of CMV retinitis differ among treatment 
centres in South Africa
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